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A B S T R A C T
Churg–Strauss syndrome is a necrotizing vasculitis of small vessels characterized by upper and lower
airway disease followed by peripheral eosinophilia and multiple organ involvement. Herein we present
the case of a 45-year-old female patient with Churg–Strauss syndrome and myopericardial disease who
improved upon cyclophosphamide treatment. Apart from discussing the characteristics of myoper-
icardial disease in eosinophilic syndromes, we highlight the crucial role of cardiac imaging in the prompt
recognition and management of such patients.
<Learning objective: Churg–Strauss syndrome is a vasculitic disorder characterized by massive
hypereosinophilia and multi-organ disease. Myocardial involvement may manifest as myopericarditis,
valvular dysfunction, myocardial infarction, or left ventricular thrombi or alternatively may only cause
subclinical changes difﬁcult to diagnose with conventional echocardiography. Cardiac magnetic
resonance imaging is the gold-standard for the detection of active inﬂammation and ﬁbrosis that may
characterize myocardial disease. This is of major importance since timely diagnosis may enable the
establishment of appropriate treatments and arrhythmia screening.>
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Churg–Strauss syndrome (CSS) is a rare necrotizing vasculitis of
small vessels. Late onset asthma, nasal polyps, and sinusitis are
early manifestations with eosinophilia and vasculitic tissue
affecting nervous system, gastrointestinal tract, skin, and lungs,
with heart involvement occurring later in the disease course.
Case report
Herein we present the case of a 45-year-old woman with CSS and
history of asthma and nasal polyps, who presented with dyspnea
(New York Heart Association III) of recent onset. On admission,
the patient was in respiratory distress with blood pressure
110/70 mmHg and inspiratory crackles. Her chest-X-ray revealed
bilateral pleural effusions and the electrocardiogram showed sinus
tachycardia of 100 bpm, left ventricular hypertrophy, and diffuse* Corresponding author at: Department of Cardiology, Laiko General Hospital,
17 Agiou Thoma Street, 11527 Goudi, Athens, Greece. Tel.: +30 2107456258;
fax: +30 2132061761.
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1878-5409/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All righthorizontal ST segment depression. Blood analysis was remarkable
for severe eosinophilia (15,000/ml), white blood cells 24,000/ml,
abnormal troponin (1.5 ng/ml), and B-type natriuretic peptide
800 pg/ml.
Initial transthoracic echocardiogram (TTE) revealed a left
ventricle (LV) of normal internal dimensions with mild systolic
dysfunction (ejection fraction = 45%), hypokinetic inferior and
inferolateral and mid/apical anteroseptal segments. There was
marked hyperechogenicity of inferior and inferolateral wall
involving both the subendocardial and subepicardial segments.
An accompanying moderate pericardial effusion causing proto-
diastolic compression of the right ventricle was present. Mitral and
tricuspid annular inﬁltrations with moderate valvular regurgita-
tion were evident as well. Right ventricular hypertrophy with
reduced tricuspid annular systolic velocity (7 cm/sec) was also
found. There were no intraventricular thrombi. Interestingly, both
global longitudinal and circumferential LV strain were severely
impaired (12% and 8%, respectively) (Fig. 1a, c and e).
The patient received cyclophosphamide (CYC) monthly doses of
2 g for six consecutive months and steroids (1 g methylpredniso-
lone/24 h  3 days switched to prednisolone with progressive
tapering) with clinical improvement soon after the ﬁrst infusion.s reserved.
Fig. 1.
Transthoracic study on admission (a, c, e) and 5 days after the ﬁrst cyclophophamide infusion (b, d, f). (a, b) Left parasternal long-axis view, transthoracic
echocardiography. Left ventricular hyperechogenicity, mitral annular inﬁltration and moderate pericardial effusion causing right ventricular protodiastolic
compression (a) are attenuated upon treatment (b). (c, d) Left parasternal short-axis view, papillary muscle level, transthoracic echocardiography. Left ventricular
and papillary muscle inﬁltration, moderate pericardial effusion. Endocardial, myocardial, subepicardial, and pericardial involvement can be demonstrated in this
view (c). Upon treatment, ongoing hyperechogenicity affecting the subepicardial and subendocardial left ventricular wall – here most prominent within the
inferior and inferolateral segments – as well as the papillary muscles probably reﬂects ongoing ﬁbrosis and may have resulted from previous subclinical
myocardial disease. All three facets of the inﬂammatory response – namely acute/chronic inﬂammation and healing/ﬁbrosis – may coexist to various degrees (d).
(e, f) Tissue Doppler examination. Reduced tricuspid annular systolic velocity (8 cm/s) reﬂecting abnormal right ventricular systolic function (e) normalizes upon
treatment (14 cm/s) (f).
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global systolic function (ejection fraction = 50–55%) with resid-
ual inferior/inferolateral hypokinesia and slightly less inﬁltra-
tion (Fig. 1b, d and f). Right ventricular function had normalized
(tricuspid annular systolic velocity = 14 cm/s). There was a smallpericardial effusion with no signs of constriction. Global left
ventricular longitudinal (GLS: 16%) and circumferential (GCS:
21%) strain had improved; however, inferior/inferolateral
segments still exhibited markedly abnormal deformation
parameters probably indicating an ongoing ﬁbrotic process
Fig. 2.
Cardiac magnetic resonance imaging 15 days after the ﬁrst cyclophosphamide infusion. Cardiac magnetic resonance examination was performed in a 1.5 T
system using short tau inversion recovery (STIR) T2-weighted (T2-W), T1-weighted (T1-W) before and after contrast media injection and late enhanced images
(LGE). (a) Electrocardiogram (ECG)-triggered, STIR T2-W sequence was performed in short axis and the signal ratio measured from the region of interest covering
the myocardium of the left ventricle (LV) as well as within a skeletal muscle in the same slice. (b, c) ECG-triggered T1-W multislice spin-echo images were
obtained in axial orientation with identical parameters before and after an intravenous bolus of 0.1 mmol/kg gadolinium diethylene triamine penta-acetic acid
(Gd-DTPA). Measurements after Gd-DTPA were started within 1 min of injection (early T1 = EGE). (d) Immediately after the second set of T1-W images, 0.1 mmol/
kg Gd-DTPA was given again and LGE images were taken 15 min later. A steady-state free-precession sequence was used for the evaluation of LV function. Images
were analyzed according to previously described protocols [5].
E.D. Papadimitraki et al. / Journal of Cardiology Cases 11 (2015) 52–5554(peak systolic strain 8%, circumferential strain 15%, respec-
tively).
Cardiac magnetic resonance imaging was performed 15 days
after the ﬁrst CYC infusion. Despite the presence of normal
biventricular systolic function and dimensions (LV ejection
fraction = 61%), all three facets of the inﬂammatory process
namely acute/chronic inﬂammation and healing were evident to
various degrees. More speciﬁcally, an increased signal intensity
ratio of 2.8 (signal intensity normalized to skeletal muscle in the
same slice, normal values < 2) indicative of edema with
abnormal early (EGE = 6, normal values < 4) and positive late
gadolinium enhancement (LGE) – illustrative of hyperemia/
capillary leak and ﬁbrosis respectively – were seen. Importantly,
ﬁbrosis was also evident in the right ventricular free wall and
apex (Fig. 2d).
The patient is now receiving monthly CYC, small doses of
metoprolol and ramipril and is reasonably well. Her global systolic
function remains normal and she has no pericardial effusion. She
undergoes periodic evaluation with 24-h Holter monitoring based
on the ﬁndings of extensive ﬁbrosis – right ventricular LGE may be
indicative of a particularly arrhythmogenic substrate – which has
shown no major abnormality so far.Discussion
CSS is a necrotizing small vessel vasculitis. Late onset asthma,
nasal polyps, and sinusitis are early disease manifestations
whereas tissue eosinophilia, pulmonary inﬁltrations, and multiple
organ dysfunction occur later in the disease course. Gastrointesti-
nal and myocardial involvement may lead to life-threatening
complications and they usually imply a demise prognosis. The
American College of Rheumatology (ACR) diagnostic criteria for
CSS include asthma, peripheral eosinophilia (>10% of white blood
cells), pulmonary inﬁltrates, mononeuropathy or polyneuropathy,
paranasal sinus abnormality, and histologic evidence of extravas-
cular eosinophil inﬁltration [1]. The presence of 4/6 ACR criteria
establishes the diagnosis.
Cardiac involvement is evident in 40–50% of the CSS cases and
carries poor prognosis. It may manifest as eosinophilic myocardi-
tis, pericarditis or tamponade, valvular heart disease, congestive
heart failure, or myocardial infarction from epicardial coronary
vasculitis. LV thrombi are common. The combination of asthma,
eosinophilia, and myocardial/pericardial involvement should alert
cardiologists toward the diagnosis of CSS in previously undiag-
nosed patients. Our patient fulﬁlled 4 criteria for CSS and based on
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involvement could safely be made.
Eosinophils are toxic pro-inﬂammatory effector cells with a
major role in inﬂammation and tissue damage observed in
eosinophil-associated diseases (CSS, eosinophilic leukemia, hyper-
eosinophilic syndrome, Loefﬂer’s endocarditis). Any process
associated with hypereosinophilia lasting for several weeks or
months may lead to eosinophilic myocarditis. Either primarily or
secondarily overproduced, eosinophils contain T-cell derived
cytokines and growth factors such as interleukin-3, granulocyte
macrophage-colony stimulating factor, and interleukin-5, capable
of inducing excessive inﬂammation, tissue damage, and ﬁbrosis.
Some of the features of myocardial CSS involvement can be
evaluated by echocardiography; however, this is not 100%
sensitive for detection of subtle changes. Inﬂammation/edema
and ﬁbrosis – perhaps reﬂecting ‘‘healed’’ inﬂammation and
accounting for diastolic dysfunction and restrictive cardiomyopa-
thy – can coexist but are not always possible to be appropriately
classiﬁed with traditional echocardiography [2]. Deformation
parameters, although not established for diagnostic purposes,
may provide useful insight in the characterization of tissue
mechanics reﬂecting histopathological changes of CSS even in
subclinical disease. Features such as diminished circumferential
strain, reduced LV torsion, and segmental post-systolic shortening
may be linked to myocardial inﬁltration/ﬁbrosis and diastolic
dysfunction or features of restrictive cardiomyopathy and enhance
the sensitivity of the method for the detection of myocardial
involvement in ambiguous cases [3].
Cardiac magnetic resonance imaging is advocated as the gold-
standard method to look for preclinical cardiac involvement in CSS
patients. This is of major importance since immunosuppression
with CYC and high-dose steroids should be promptly instituted in
the case of heart – or other major organ – involvement. Cardiac
magnetic resonance imaging can assess disease acuity using T2
imaging that provides edema evaluation. Additionally, if 2/3
evaluated parameters are positive (T2, EGE, LGE), this is a proof of
myocardial inﬂammation. Finally, the location and extent ofmyocardial scar have a prognostic value, even if LV systolic
function remains intact. In our case the LGE = 10% of LV extent had
a pattern of diffuse subendocardial ﬁbrosis and involved also right
ventricle. These ﬁndings carry a poor prognosis and also suggest
careful evaluation for future arrhythmia development [4].
To conclude, echocardiography, using the current techniques, is
a cheap, bedside, widely available tool that can imply the diagnosis
in the appropriate clinical context, and also be used for follow-up.
However, its sensitivity, even with the use of new echocardio-
graphic techniques is questionable for the diagnosis of subtle
disease. At the moment, cardiac magnetic resonance imaging can
answer queries about tissue characterization, disease acuity, and
prediction in these patients.
Informed consent has been obtained by the patient for
publication of this case report and accompanying images.
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